Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DLZVY
ADC Name
SC-007
Synonyms
SC 007; SC-007; SC007
   Click to Show/Hide
Organization
Stemcentrx, Inc.; AbbVie, Inc.
Drug Status
Phase 1 (Terminated)
Indication
In total 3 Indication(s)
Colorectal cancer
Phase 1
Clinical Trial
Gastric cancer
Phase 1
Clinical Trial
Oesophageal cancer
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
Undisclosed
Antibody Name
Undisclosed
Antigen Name
Undisclosed
Payload Name
Undisclosed
Linker Name
Undisclosed
Conjugate Type
Undisclosed
ChEBI ID
CHEMBL4297824
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT03253185
Phase 1
An open label study of SC-007 in subjects with advanced cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Patients Enrolled
Patients with advanced cancer (Colorectal Cancer or Gastric Cancer).
Administration Dosage
SC-007 iv.
Related Clinical Trial
NCT Number NCT03253185  Clinical Status Phase 1
Clinical Description An open label study of SC-007 in subjects with advanced cancer.
References
Ref 1 An Open Label Study of SC-007 in Subjects With Advanced Cancer